文献速递浆细胞疾病

循环浆细胞检测可改善新诊断多发性骨髓瘤R-ISS风险分层

The detection of circulating plasma cells may improve the Revised International Staging System (R-ISS) risk stratification of patients with newly diagnosed multiple myeloma.
PubMed 文献 · Br J Haematol · 2021-04-01

该回顾性分析纳入2005至2017年单中心161例多发性骨髓瘤患者,评估诊断时循环浆细胞(CPC)检测能否在R-ISS三个风险组内进一步区分预后。提示诊断时检测CPC可作为进一步预后生物标志物改善R-ISS II患者风险分层。

要点

  • R-ISS II患者中无CPC者OS和PFS优于≥1个CPC者。
  • 诊断时CPC检测或可改善R-ISS II风险分层。
  • 该结论来自单中心161例回顾性分析。

核心结论

  • 诊断时检测循环浆细胞可能作为进一步预后生物标志物,改善R-ISS II期多发性骨髓瘤患者的风险分层。

研究设计与样本

  • 回顾性分析纳入2005至2017年单中心治疗的161例多发性骨髓瘤患者。

临床怎么用

  • 对新诊断多发性骨髓瘤患者,尤其R-ISS II期,可考虑诊断时检测循环浆细胞以辅助预后分层。

局限性

  • 本研究为单中心回顾性分析,样本量161例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Revised International Staging System (R-ISS) stratifies patients affected by Multiple Myeloma (MM) into three distinct risk groups: R-ISS I [ISS Stage I, Standard-Risk cytogenetics and normal Lactase DeHydrogenase (LDH)], R-ISS III (ISS stage III and either high-risk cytogenetics or high LDH) and R-ISS II (any other characteristics). With the aim to verify whether the three R-ISS groups could be divided into subgroups with different prognostic factors based on the detection of Circulating Plasma Cells (CPCs) at diagnosis, in this retrospective analysis, we evaluated 161 patients with MM treated at our centre between 2005 and 2017. In all, 57 patients (33·9%) were staged as R-ISS III, 98 (58·3%) as R-ISS II and six (3·6%) as R-ISS I. CPCs were detected in 125 patients (74·4%), while in 43 patients (25·6%) no CPCs were seen. Our analysis revealed that Overall Survival (OS) and progression-free survival (PFS) rates in R-ISS II patients were higher in the subgroup without CPCs compared to the subgroup with ≥1 CPCs (OS: 44·7% vs. 16·3%, P = 0·0089; PFS: 27·8% vs. 8·1%, P = 0·0118). Our present findings suggest that the detection of CPCs at diagnosis may be used as a further prognostic biomarker to improve the risk stratification of patients with MM staged as R-ISS II.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Galieni P, Travaglini F, Vagnoni D, et al. The detection of circulating plasma cells may improve the Revised International Staging System (R-ISS) risk stratification of patients with newly diagnosed multiple myeloma. Br J Haematol. 2021. PMID: 33792026. doi:10.1111/bjh.17118

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。